Welgene Biotech Co.,Ltd. (TPEX:6661)

Market Cap	414.82M -21.9%
Revenue (ttm)	375.94M +16.6%
Net Income	1.33M +20.1%
EPS	0.06 +26.3%
Shares Out	23.30M
PE Ratio	311.89
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	15,302
Average Volume	8,589
Open	17.55
Previous Close	17.95
Day's Range	17.30 - 17.90
52-Week Range	17.30 - 24.05
Beta	0.23
RSI	35.77
Earnings Date	May 15, 2026

About Welgene Biotech

Welgene Biotech Co.,Ltd. engages in the trade of biotechnology-related instruments, reagents, and biotechnology testing services. The company offers research services, including generation, PacBio third generation sequencing; microarray, protein body analysis; nucleic acid extraction/QC, single cell experimental, and bioinformatics analysis services. It also provides reagents, medical consumables, and instruments, as well as software services. Welgene Biotech Co.,Ltd. was founded in 2003 and is based in Taipei City, Taiwan.

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2003
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6661

Financial Performance

In 2025, Welgene Biotech's revenue was 375.94 million, an increase of 16.55% compared to the previous year's 322.55 million. Earnings were 1.33 million, an increase of 20.14%.